Spots Global Cancer Trial Database for invasive ductal breast cancer
Every month we try and update this database with for invasive ductal breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | NCT01583426 | Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... Tubular Breast ... HER-2 Positive ... Inflammatory Br... Inflammatory Br... | nab-Paclitaxel Paclitaxel | 18 Years - | German Breast Group | |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer | NCT02199418 | Tubular Breast ... Mucinous Breast... Invasive Ductal... Inflammatory Br... | Paclitaxel Cisplatin | 18 Years - 70 Years | RenJi Hospital | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer | NCT01426880 | Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... Tubular Breast ... HER-2 Positive ... Inflammatory Br... Inflammatory Br... | Carboplatin background trea... | 18 Years - | German Breast Group | |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer | NCT03749850 | Metastatic Brea... Breast Cancer Breast Neoplasm... Stage IV Breast... Metastatic Canc... Invasive Ductal... Invasive Ductal... Adenocarcinoma ... | LTLD MR-HIFU induced... Cyclophosphamid... | 18 Years - | UMC Utrecht | |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | NCT02879513 | Invasive Ductal... Tubular Breast ... Mucinous Breast... Inflammatory Br... | Paclitaxel Cisplatin Epirubicin Cyclophosphamid... 5-fluoruracil | 18 Years - 70 Years | RenJi Hospital | |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | NCT02879513 | Invasive Ductal... Tubular Breast ... Mucinous Breast... Inflammatory Br... | Paclitaxel Cisplatin Epirubicin Cyclophosphamid... 5-fluoruracil | 18 Years - 70 Years | RenJi Hospital | |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | NCT02221999 | Tubular Breast ... Mucinous Breast... Invasive Ductal... Inflammatory Br... | Paclitaxel Cisplatin Gonadotropin-re... Letrozole | 18 Years - 70 Years | RenJi Hospital | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer | NCT03749850 | Metastatic Brea... Breast Cancer Breast Neoplasm... Stage IV Breast... Metastatic Canc... Invasive Ductal... Invasive Ductal... Adenocarcinoma ... | LTLD MR-HIFU induced... Cyclophosphamid... | 18 Years - | UMC Utrecht | |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) | NCT02682693 | Breast Cancer F... Tubular Breast ... Mucinous Breast... Invasive Ductal... HER2 Positive B... Inflammatory Br... Tubular Breast ... | Denosumab nab-Paclitaxel Epirubicin Cyclophosphamid... Carboplatin Trastuzumab Pertuzumab | 18 Years - 75 Years | German Breast Group | |
| Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT) | NCT01960803 | Invasive Ductal... Carcinoma Breas... | Intraoperative ... | 50 Years - 95 Years | Advocate Health Care |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
